DIGI-INTERNATIONAL
21.6.2022 09:02:08 CEST | Business Wire | Press release
Digi International ® , (NASDAQ: DGII) - a leading global provider of Internet of Things (IoT) connectivity products, solutions, services and wireless data plans - today announced it will showcase a wide range of its new solutions and devices at Embedded World 2022 that enable medical, transportation, agriculture and industrial enterprises to create innovative solutions faster.
Digi’s first-look of its Digi ConnectCore MP1 system-on-modules, Digi ConnectCore Voice Control software, and Digi XBee Intelligent Edge Controller takes place at Bressner Technology booth 1-236 in Hall 1. Digi ConnectCore MP1 is also on display at STMicroelectronics Wall of SOMs booth 4A-148. There are live demos of Digi XBee and its IX15 gateway and the new Digi ConnectCore Voice Control application at the NXP booth 4A-222.
Bolstered by Digi Remote Manager® —the command center of an intelligent network—Digi’s new and smaller embedded IoT technologies dramatically improve the way people, machines and processes interact. Network connectivity is the fundamental key to the true potential of these technologies that place Digi at the forefront of some of the most advanced networking solutions combining software, hardware and services for enterprises.
“This is an exceptionally exciting year to return to Embedded World,” said Andreas Burghart, Senior Product Manager at Digi. “Advances in connectivity and IoT devices are spurring the rapid development of next-generation, cost-effective, integrated solutions. That’s unleashing new waves of innovation across numerous industries that require reliable and secure connectivity. We’re looking forward to sharing our progress and collaborating with our customers on breakthrough embedded solutions.”
Digi’s Embedded World 2022 solution showcase includes three new or recently launched products:
- Digi ConnectCore® MP1 Family – The Digi ConnectCore® MP1 family of system-on-modules (SOMs) features the industry’s smallest STM32MP1 SOM that integrates Wi-Fi, Bluetooth and wired connectivity without comprising design flexibility. The solution also features its Connected Device platform and well-tested development tools and design support. Digi ConnectCore MP1 SOMs offer a cost-effective wireless solution for OEMs seeking to reduce product-development risk and effort.
- Digi ConnectCore Voice Control Software – This advanced voice-control software solution is designed for the acclaimed ConnectCore family of system-on-modules (SOMs). Digi ConnectCore Voice Control is a fully integrated, ready-to use software solution that enables developers to design a voice-based human-machine interface (HMI) to control device operations using speech. It provides voice processing on edge devices (including support for 30 languages and a 60,000-word vocabulary) with no cloud connectivity required. That reduces connectivity costs and data-privacy concerns while providing response times of less than 100ms.
- Digi XBee® Intelligent Edge Controller (IEC) - The Digi XBee® Intelligent Edge Controller (IEC) delivers a comprehensive networking architecture to close the gap between field devices and the cloud and provide powerful asset monitoring and control. In combination with Digi X-ON cloud, the Digi XBee IEC helps companies monitor sensors or remote-control assets over long-range, low-power wide area networks, including LoRaWAN, CAT-M1, and NB-IoT. Industrial devices can be monitored with sub-second latency with alarms and data wirelessly delivered through the Digi X-ON cloud.
At Embedded World, Digi will also demonstrate its wireless IoT solution for smart agriculture with a simulation of a complete ecosystem that can centrally manage multiple farms. This end-to-end solution provides crop managers with real-time weather conditions that help determine optimal irrigation cycles, maximize crop yields and lower labor and supply costs. The heart of the system is the Digi IX15 gateway and cellular router that communicates with irrigation pumps through a wireless mesh network of Digi XBee® modules. Using Digi Remote Manager® and a cloud-based web application, a crop manager monitors exact weather and soil conditions at each farm, and controls individual pumps. The commands pass through the internet to the IX15 by a cellular network, and the IX15 relays the commands to the XBee modules at each pump, turning them on and off remotely.
Digi will also preview its upcoming Digi ConnectCore 93, which includes NXP’s i.MX 93 system-on-a-chip (SOC). Digi is one of six Early Access Partners for this April 2023 release.
For more information about Digi, stop by Bresser Technology Booth 1-236 in Hall 1 or visit: www.digi.com .
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005096/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom